|
[1]
|
Johnston S, Pippen J, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer [J]. J Clin Oncol, 2009, 27(33):5538-5546. doi: 10.1200/JCO.2009.23.3734
|
|
[2]
|
Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with HR+breast cancer: bolero-2 final progression-free survival analysis[J]. Adv Ther, 2013, 30(10):870-884. doi: 10.1007/s12325-013-0060-1
|
|
[3]
|
Finn RS, Martin M, Rugo HS, et al. PALOMA-2: Primary results from a phase Ⅲ trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER-2-advanced breast cancer (ABC)[J]. J Clin Oncol, 2016, 34(suppl):abstr 507. doi: 10.1200/JCO.2016.34.15_suppl.507
|
|
[4]
|
Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as FirstLine Therapy for HR-Positive, Advanced Breast Cancer[J]. N Engl J Med, 2016, 375(18):1738-1748. doi: 10.1056/NEJMoa1609709
|
|
[5]
|
Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as firstline therapy for HR-positive, advanced breast cancer[J]. N Engl J Med, 2016, 375(18):1738-1748. doi: 10.1056/NEJMoa1609709
|
|
[6]
|
Robertson JFR, Bondarenko IM, Trishkina PR, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial[J]. Lancet, 2017, 388(10063):2997-3005. http://www.medicinesresources.nhs.uk/en/Medicines-Awareness/Primary-Research/Randomised-controlled-trials/Fulvestrant-500-mg-versus-anastrozole-1-mg-for-hormone-receptor-positive-advanced-breast-cancer-FALCON-an-international--6361603656/
|
|
[7]
|
Ro J, Andre F, Loi S, et al. PALOMA3: A double-blind, phase Ⅲ trial of fulvestrant with or without palbociclib in pre-and post-menopausal women with hormone receptor-positive, HER-2-negative metastatic breast cancer that progressed on prior endocrine therapy[J]. J Clin Oncol, 2015, 33(18 suppl):502. doi: 10.1200/jco.2015.33.18_suppl.lba502
|
|
[8]
|
Ozaki A, Tanimoto T, Saji S. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer[J]. N Engl J Med, 2015, 373(17):209-219. doi: 10.1056/NEJMoa1505270
|
|
[9]
|
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2[J]. N Engl J Med, 2001, 344(11):783-792. doi: 10.1056/NEJM200103153441101
|
|
[10]
|
Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER-2-positive breast cancer[J]. New Engl J Med, 2005, 353(16):1673-1684. doi: 10.1056/NEJMoa052122
|
|
[11]
|
Semiglazov V, Eiermann W, Zambetti M, et al. Surgery following neoadjuvant therapy in patients with HER-2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study[J]. Eur J Surg Oncol, 2011, 37(10):856-863. doi: 10.1016/j.ejso.2011.07.003
|
|
[12]
|
Chan A, MD, Delaloge S, Holmes FA, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER-2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2016, 17(3):367-377. doi: 10.1016/S1470-2045(15)00551-3
|
|
[13]
|
Cameron D, Casey M, Press M, et al. A phase Ⅲ randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses[J]. Breast Cancer Res Treat, 2008, 112(3):533-543. doi: 10.1007/s10549-007-9885-0
|
|
[14]
|
Giordano SB, Kaklamani V. Lapatinib in combination with paclitaxel for the treatment of patients with metastatic breast cancer whose tumors overexpress HER-2[J]. Breast Cancer Manag, 2013, 2(6):529-535. doi: 10.2217/bmt.13.55
|
|
[15]
|
Harbeck N, Huang CS, Hurvitz S, et al. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER-2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2016. 17(3):357-366. doi: 10.1016/S1470-2045(15)00540-9
|
|
[16]
|
Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer[J]. New Engl J Med, 2012, 366 (2):109-119. doi: 10.1056/NEJMoa1113216
|
|
[17]
|
Pegram MD, Blackwell K, Miles D, et al. Primary results from EMILIA, a phase Ⅲ study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER-2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane[J]. J Clin Oncol, 2012, 30(14 Suppl):98.
|
|
[18]
|
Ellis PA, Barrios CH, Eiermann W, et al. Phase Ⅲ, randomized study of trastuzumab emtansine (T-DM1) {+/-} pertuzumab (P) vs trastuzumab+taxane (HT) for first-line treatment of HER-2-positive MBC: primary results from the MARIANNE study[J]. J Clin Oncol, 2015, 33 (suppl):Abstract 507. https://www.researchgate.net/publication/279022015_Phase_II_Randomized_Study_of_Trastuzumab_Emtansine_Versus_Trastuzumab_Plus_Docetaxel_in_Patients_With_Human_Epidermal_Growth_Factor_Receptor_2-Positive_Metastatic_Breast_Cancer
|
|
[19]
|
O'Regan R, Ozguroglu M, Andre F, et al. Phase Ⅲ, randomized, doubleblind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer(BOLERO-3)[J]. J Clin Oncol, 2013, 31(15 Suppl): 505. http://meetinglibrary.asco.org/content/82095
|
点击查看大图
下载:
